News & Updates

In the second-line treatment of patients advanced oesophageal cancer, the use of programmed cell death 1 (PD-1) inhibitors yields more favourable outcomes than chemotherapy across multiple patient subgroups, according to the results of a meta-analysis.

New drug applications approved by US FDA as of 16-30 November 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Renal function considerably decreases over the long term for most bladder cancer patients who underwent radical cystectomy, a study has found.

Elevated expression of the factor H-related protein 1 (FHR-1) seems to be a risk factor for atherosclerotic cardiovascular disease (ACVD), a recent study has found.